Key facts
- It has raised $7.4M; the latest was Early Stage VC ($7.4M) in Mar 2026.
- Notable investors include Tsinghua Innovation Ventures, Yuanhui Investment, Dehua Ventures, Fresscon Capital, Sunz Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Infinity Scope
- ·The full record, as it builds
Funding rounds
No funding rounds for Infinity Scope are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Infinity Scope
Developer of biotechnology research solutions focused on multiomics analysis and spatial biology technologies for life science applications. It enables single-cell sequencing, protein detection, bioinformatics analysis, spatial data modeling and research services for scientific institutions, enabling advanced biological research and precision medicine development.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2023
- Website
- infinityscopebio.com/
- Ownership
- Privately Held (backing)
Infinity Scope doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Infinity Scope shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Infinity Scope in its N-PORT filings yet. We sweep new filings monthly.